Citi analyst Daniel Grosslight raised the firm’s price target on Hims & Hers to $28 from $24 and keeps a Neutral rating on the shares post the Q1 report. The company is entering a transition phase by lessening its reliance on compounded GLP-1s, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Closing Bell Movers: Hims & Hers down 12% on earnings miss
- HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets
- Bullish flow in Hims and Hers Health with shares up 3.13%
- Notable companies reporting after market close
- Hims & Hers Health reports Q1 EPS (40c) vs 20c last year